Citigroup
RCUS icon

Citigroup’s Arcus Biosciences RCUS Stock Holding History

Citigroup’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30,000
Closed -$648K – 6159
2026
Q1 		$648K Hold
30,000
– – ﹤0.01% 3389
2025
Q4 		$715K Buy
30,000
+200
+0.7% +$4.08K ﹤0.01% 3361
2025
Q3 		$405K Hold
29,800
– – ﹤0.01% 3678
2025
Q2 		$243K Sell
29,800
-29,900
-50% -$255K ﹤0.01% 3975
2025
Q1 		$469K Buy
59,700
+29,800
+100% +$345K ﹤0.01% 3718
2024
Q4 		$445K Buy
+29,900
New +$488K ﹤0.01% 3913
2023
Q1 		– Sell
-20,000
Closed -$414K – 5796
2022
Q4 		$414K Buy
20,000
+2,000
+11% +$55K ﹤0.01% 3306
2022
Q3 		$471K Buy
18,000
+12,200
+210% +$323K ﹤0.01% 3272
2022
Q2 		$147K Sell
5,800
-1,700
-23% -$41.6K ﹤0.01% 4014
2022
Q1 		$237K Buy
+7,500
New +$251K ﹤0.01% 3989
2021
Q4 		– Sell
-50,500
Closed -$1.76M – 6049
2021
Q3 		$1.76M Buy
+50,500
New +$1.57M ﹤0.01% 2634

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Citigroup's RCUS Position: Q2 2026 in Review

Citigroup increased its Arcus Biosciences (RCUS) stake by 325% in Q2 2026, buying an estimated $2.12M and bringing the position to 112,238 shares worth $3.46M. The position accounts for ﹤0.01% of the portfolio, ranked #2466.

Citigroup first reported a position in RCUS in Q1 2018 and has held it in 34 quarters since. The position peaked at $6.42M in Q1 2023. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Citigroup held 112,238 shares of Arcus Biosciences worth $3.46M as of Q2 2026.
  • Citigroup bought 85,842 Arcus Biosciences shares in Q2 2026, an estimated $2.12M.
  • Arcus Biosciences made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2466 holding.
  • Citigroup first reported a position in Arcus Biosciences in Q1 2018 and has held it in 34 quarters since.
  • Citigroup's Arcus Biosciences position peaked at $6.42M in Q1 2023.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.